Wang, Jiun-LingJiun-LingWangLee, Ching-ChiChing-ChiLeeKo, Wen-ChienWen-ChienKoWu, Li-ChiuLi-ChiuWuCHIA-HSUIN CHANG2025-06-242025-06-242025-06-10https://scholars.lib.ntu.edu.tw/handle/123456789/730226Aims: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) demonstrate pleiotropic effects, notably encompassing anti-inflammatory properties. We aim to compare the association of GLP-1RAs versus dipeptidyl peptidase-4 inhibitors (DPP4is) with hospitalization due to various infectious diseases. Methods: This population-based retrospective cohort study used data from the Taiwan National Health Insurance in 2016–2021. A total of 455,003 patients with type 2 diabetes were identified. We conducted a 1:1 propensity score-matched analysis of patients initiating GLP-1RA or DPP4i therapy. The outcomes assessed were hospitalizations due to various infections. Results: In the matched cohort, we identified 17,706 GLP-1RA and 17,706 DPP4i initiators. GLP-1RA initiators exhibited a significantly lower risk of hospitalization due to lower respiratory tract infections (adjusted HR: 0.56; 95% CI, 0.49 to 0.65) and diabetic foot infections (adjusted HR: 0.77; CI, 0.65 to 0.91), but not intraabdominal (adjusted HR: 0.91; CI, 0.73 to 1.13) or reproductive and urinary tract infections (adjusted HR: 0.98; CI, 0.75 to 1.27) as compared with DPP4i initiators. Conclusion: Our study demonstrates that GLP-1RA administration offers advantages over DPP4is in reducing the incidence of severe lower respiratory tract infections and diabetic foot infections requiring hospitalization in individuals with type 2 diabetes.enDiabetes mellitusDipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1 receptor agonistsInfection[SDGs]SDG3journal article10.1016/j.diabres.2025.11232440505816